Volanesorsen - PharmaKB

Volanesorsen

Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
hereditary congenital and neonatal diseases and abnormalities	D009358
nutritional and metabolic diseases	D009750

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
acne free blackhead removing scrub 2 salicylic acid with charcoal	C200263	2025-07-24
aha glycolic acid foam cleanser (sulfate-free)- 7.5 oz	C200263	2024-12-16
clear days ahead	C200263	2024-11-19
lactic acid free for sportswoman synergy	OTC monograph not final	2017-01-01
lactic acid free m synergy	OTC monograph not final	2016-10-24
oil free acne scrub	OTC monograph final	2010-07-08
peach slices 3 step acne starter kit	C200263	2024-08-14
premasol - sulfite-free (amino acid)	ANDA	2022-08-04
walgreens oil-free acne wash	C200263	2024-06-03

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C10: Lipid modifying agents

— C10A: Lipid modifying agents, plain

— C10AX: Other lipid modifying agents in atc

— C10AX18: Volanesorsen

HCPCS

No data

Clinical

Clinical Trials

1733 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	9	20	19	3	12	62
Healthy volunteers/patients	—	—	—	34	3	1	2	22	61
Diabetes mellitus	D003920	EFO_0000400	E08-E13	3	11	3	12	28	54
Obesity	D009765	EFO_0001073	E66.9	3	4	3	5	31	43
Hepatitis c	D006526	—	B19.2	1	20	20	3	1	41
Type 2 diabetes mellitus	D003924	EFO_0001360	E11	1	7	1	7	24	38
Hiv infections	D015658	EFO_0000764	B20	4	7	14	7	6	37
Insulin resistance	D007333	EFO_0002614	E88.819	—	8	—	3	23	34
Chronic hepatitis c	D019698	EFO_0004220	B18.2	—	14	19	1	2	33
Non-small-cell lung carcinoma	D002289	—	—	8	22	6	1	2	33

Show 221 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Colorectal neoplasms	D015179	—	—	7	26	9	—	9	48
Leukemia	D007938	—	C95	8	11	9	—	1	27
Myeloid leukemia acute	D015470	—	C92.0	7	19	1	—	2	26
Prostatic neoplasms	D011471	—	C61	3	6	6	—	6	20
Stomach neoplasms	D013274	EFO_0003897	C16	4	8	3	—	5	18
Pancreatic neoplasms	D010190	EFO_0003860	C25	5	8	2	—	4	17
Melanoma	D008545	—	—	3	10	1	—	3	17
Myelodysplastic syndromes	D009190	—	D46	6	7	3	—	—	15
Carcinoma	D002277	—	C80.0	5	6	3	—	2	15
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	2	3	8	—	3	15

Show 171 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Overweight	D050177	—	E66.3	2	1	—	—	9	12
Esophageal neoplasms	D004938	—	C15	4	4	—	—	2	9
Hematologic neoplasms	D019337	—	—	2	6	—	—	1	8
Myeloid leukemia	D007951	—	C92	5	4	—	—	—	8
Renal cell carcinoma	D002292	EFO_0000376	—	1	6	—	—	—	7
Glioblastoma	D005909	EFO_0000515	—	2	3	—	—	1	6
Acute kidney injury	D058186	—	N17	—	2	—	—	4	6
Metabolic diseases	D008659	EFO_0000589	E88.9	—	1	—	—	5	6
Hidradenitis suppurativa	D017497	—	L73.2	2	2	—	—	2	5
Human influenza	D007251	EFO_0007328	J11.1	1	2	—	—	2	5

Show 139 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Therapeutic equivalency	D013810	—	—	3	—	—	—	1	4
Myelomonocytic leukemia chronic	D015477	—	C93.1	3	—	—	—	—	3
Urticaria	D014581	EFO_0005531	L50	1	—	—	—	2	3
Hypoxia	D000860	—	R09.02	2	—	—	—	1	3
Biliary tract neoplasms	D001661	—	C24.9	1	—	—	—	2	3
Schizophrenia	D012559	EFO_0000692	F20	2	—	—	—	1	3
Affect	D000339	—	—	1	—	—	—	1	2
Gastric bypass	D015390	EFO_0005244	—	1	—	—	—	1	2
Alveolar soft part sarcoma	D018234	—	—	2	—	—	—	—	2
Neurofibrosarcoma	D018319	—	—	2	—	—	—	—	2

Show 56 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Exercise	D015444	EFO_0000483	—	—	—	—	—	8	8
Phenylketonurias	D010661	—	E70.0	—	—	—	—	8	8
Wound healing	D014945	GO_0042060	—	—	—	—	—	6	6
Sarcopenia	D055948	EFO_1000653	M62.84	—	—	—	—	5	5
Fatigue	D005221	—	R53.83	—	—	—	—	4	4
Irritable bowel syndrome	D043183	EFO_0000555	K58	—	—	—	—	4	4
Biological availability	D001682	—	—	—	—	—	—	4	4
Gastrointestinal diseases	D005767	—	—	—	—	—	—	4	4
Sepsis	D018805	EFO_0001420	A41.9	—	—	—	—	3	3
Myopia	D009216	EFO_0003927	H52.1	—	—	—	—	3	3

Show 275 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Volanesorsen
INN	volanesorsen
Description	Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII).
Classification	Oligonucleotide
Drug class	antisense oligonucleotides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—